1887

Abstract

A comprehensive meningococcal vaccine is yet to be developed. In the absence of a vaccine that immunizes against the serogroup B capsular polysaccharide, this can only be achieved by targeting subcapsular antigens, and a number of outer-membrane proteins (OMPs) are under consideration as candidates. A major obstacle to the development of such a vaccine is the antigenic diversity of these OMPs, and obtaining population data that accurately identify and catalogue these variants is an important component of vaccine design. The recently proposed meningococcal molecular strain-typing scheme indexes the diversity of two OMPs, PorA and FetA, that are vaccine candidates, as well as the capsule and multilocus sequence type. This scheme was employed to survey 323 meningococci isolated from invasive disease in England and Wales from 1975 to 1995, before the introduction of meningococcal conjugated serogroup C polysaccharide vaccines in 1999. The eight-locus typing scheme provided high typeability (99.4 %) and discrimination (Simpson's diversity index 0.94–0.99). The data showed cycling of meningococcal genotypes and antigenic types in the absence of planned interventions. Notwithstanding high genetic and antigenic diversity, most of the isolates belonged to one of seven clonal complexes, with 11 predominant strain types. Combinations of PorA and FetA, chosen on the basis of their prevalence over time, generated vaccine recipes that included protein variants found in 80 % or more of the disease isolates for this time period. If adequate immune responses can be generated, these results suggest that control of meningococcal disease with relatively simple protein component vaccines may be possible.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.2007/014761-0
2008-04-01
2019-11-23
Loading full text...

Full text loading...

/deliver/fulltext/micro/154/4/1170.html?itemId=/content/journal/micro/10.1099/mic.0.2007/014761-0&mimeType=html&fmt=ahah

References

  1. Achtman, M. ( 1997; ). Microevolution and epidemic spread of serogroup A Neisseria meningitidis – a review. Gene 192, 135–140.[CrossRef]
    [Google Scholar]
  2. Bjune, G., Høiby, E. A., Grønnesby, J. K., Arnesen, O., Fredriksen, J. H., Halstensen, A., Holten, E., Lindbak, A. K., Nøkleby, H. & other authors ( 1991; ). Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093–1096.[CrossRef]
    [Google Scholar]
  3. Brehony, C., Jolley, K. A. & Maiden, M. C. ( 2007; ). Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 31, 15–26.[CrossRef]
    [Google Scholar]
  4. Bygraves, J. A., Urwin, R., Fox, A. J., Gray, S. J., Russell, J. E., Feavers, I. M. & Maiden, M. C. J. ( 1999; ). Population genetic and evolutionary approaches to the analysis of Neisseria meningitidis isolates belonging to the ET-5 complex. J Bacteriol 181, 5551–5556.
    [Google Scholar]
  5. Caugant, D. A. ( 1998; ). Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 106, 505–525.[CrossRef]
    [Google Scholar]
  6. Caugant, D. A. ( 2001; ). Global trends in meningococcal disease. In Meningococcal Disease: Methods and Protocols, pp. 273–294. Edited by A. J. Pollard & M. C. J. Maiden. Totowa, NJ: Humana Press.
  7. Elias, J., Harmsen, D., Claus, H., Hellenbrand, W., Frosch, M. & Vogel, U. ( 2006; ). Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis 12, 1689–1695.[CrossRef]
    [Google Scholar]
  8. Feavers, I. M., Gray, S. J., Urwin, R., Russell, J. E., Bygraves, J. A., Kaczmarski, E. B. & Maiden, M. C. J. ( 1999; ). Multilocus sequence typing and antigen gene sequencing in the investigation of a meningococcal disease outbreak. J Clin Microbiol 37, 3883–3887.
    [Google Scholar]
  9. Finne, J., Leinonen, M. & Makela, P. H. ( 1983; ). Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2, 355–357.
    [Google Scholar]
  10. Gold, R., Lepow, M. L., Goldschneider, I., Draper, T. F. & Gotshlich, E. C. ( 1979; ). Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 140, 690–697.[CrossRef]
    [Google Scholar]
  11. Gupta, S. & Maiden, M. C. J. ( 2001; ). Exploring the evolution of diversity in pathogen populations. Trends Microbiol 9, 181–185.[CrossRef]
    [Google Scholar]
  12. Gupta, S., Maiden, M. C. J., Feavers, I. M., Nee, S., May, R. M. & Anderson, R. M. ( 1996; ). The maintenance of strain structure in populations of recombining infectious agents. Nat Med 2, 437–442.[CrossRef]
    [Google Scholar]
  13. Harrison, L. H., Jolley, K. A., Shutt, K. A., Marsh, J. W., O'Leary, M., Sanza, L. T. & Maiden, M. C. ( 2006; ). Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 193, 1266–1274.[CrossRef]
    [Google Scholar]
  14. Hunter, P. R. & Gaston, M. A. ( 1988; ). Numerical index of discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol 26, 2465–2466.
    [Google Scholar]
  15. Jodar, L., Feavers, I. M., Salisbury, D. & Granoff, D. M. ( 2002; ). Development of vaccines against meningococcal disease. Lancet 359, 1499–1508.[CrossRef]
    [Google Scholar]
  16. Jolley, K. A. & Maiden, M. C. ( 2006; ). AgdbNet – antigen sequence database software for bacterial typing. BMC Bioinformatics 7, 314 [CrossRef]
    [Google Scholar]
  17. Jolley, K. A., Kalmusova, J., Feil, E. J., Gupta, S., Musilek, M., Kriz, P. & Maiden, M. C. ( 2000; ). Carried meningococci in the Czech Republic: a diverse recombining population. J Clin Microbiol 38, 4492–4498.
    [Google Scholar]
  18. Jolley, K. A., Chan, M. S. & Maiden, M. C. ( 2004; ). mlstdbNet – distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 5, 86 [CrossRef]
    [Google Scholar]
  19. Jolley, K. A., Brehony, C. & Maiden, M. C. ( 2007; ). Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 31, 89–96.[CrossRef]
    [Google Scholar]
  20. Jones, D. M. & Sutcliffe, E. M. ( 1990; ). Group A meningococcal disease in England associated with the Haj. J Infect 21, 21–25.[CrossRef]
    [Google Scholar]
  21. Maiden, M. C. ( 2002; ). Population structure of Neisseria meningitidis. In Emerging Strategies in the Fight Against Meningitis: Molecular and Cellular Aspects, pp. 151–170. Edited by C. Ferreirós, M. T. Criado & J. Vázquez. Wymondham, Norfolk: Horizon Scientific Press.
  22. Maiden, M. C. ( 2004; ). Dynamics of bacterial carriage and disease: lessons from the meningococcus. Adv Exp Med Biol 549, 23–29.
    [Google Scholar]
  23. Maiden, M. C. J., Bygraves, J. A., Feil, E., Morelli, G., Russell, J. E., Urwin, R., Zhang, Q., Zhou, J., Zurth, K. & other authors ( 1998; ). Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95, 3140–3145.[CrossRef]
    [Google Scholar]
  24. Miller, E., Salisbury, D. & Ramsay, M. ( 2001; ). Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 (Suppl. 1), S58–S67.[CrossRef]
    [Google Scholar]
  25. O'Hallahan, J., Lennon, D. & Oster, P. ( 2004; ). The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 23, S293–S298.
    [Google Scholar]
  26. Oster, P., Lennon, D., O'Hallahan, J., Mulholland, K., Reid, S. & Martin, D. ( 2005; ). MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23, 2191–2196.[CrossRef]
    [Google Scholar]
  27. Perkins, B. A., Jonsdottir, K., Briem, H., Griffiths, E., Plikaytis, B. D., Hoiby, E. A., Rosenqvist, E., Holst, J., Nokleby, H. & other authors ( 1998; ). Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 177, 683–691.[CrossRef]
    [Google Scholar]
  28. Perrett, K. P. & Pollard, A. J. ( 2005; ). Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 5, 1611–1625.[CrossRef]
    [Google Scholar]
  29. Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Arico, B., Comanducci, M., Jennings, G. T., Baldi, L., Bartolini, E. & other authors ( 2000; ). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816–1820.[CrossRef]
    [Google Scholar]
  30. Russell, J. E., Jolley, K. A., Feavers, I. M., Maiden, M. C. & Suker, J. S. ( 2004; ). PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 10, 674–678.[CrossRef]
    [Google Scholar]
  31. Sacchi, C. T., Whitney, A. M., Popovic, T., Beall, D. S., Reeves, M. W., Plikaytis, B. D., Rosenstein, N. E., Perkins, B. A., Tondella, M. L. & other authors ( 2000; ). Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J Infect Dis 182, 1169–1176.[CrossRef]
    [Google Scholar]
  32. Sierra, G. V. G., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P. L., Sotolongo, P. F., Casanueva, G. V., Rico, C. O., Rodriguez, C. R. & other authors ( 1991; ). Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14, 195–207.
    [Google Scholar]
  33. Simpson, E. H. ( 1949; ). Measurement of diversity. Nature 163, 688 [CrossRef]
    [Google Scholar]
  34. Staden, R. ( 1996; ). The Staden sequence analysis package. Mol Biotechnol 5, 233–241.[CrossRef]
    [Google Scholar]
  35. Stein, D. M., Robbins, J., Miller, M. A., Lin, F. Y. & Schneerson, R. ( 2006; ). Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? Vaccine 24, 221–228.[CrossRef]
    [Google Scholar]
  36. Stephens, D. S. ( 2007; ). Conquering the meningococcus. FEMS Microbiol Rev 31, 3–14.[CrossRef]
    [Google Scholar]
  37. Suker, J., Feavers, I. M., Achtman, M., Morelli, G., Wang, J.-F. & Maiden, M. C. J. ( 1994; ). The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol 12, 253–265.[CrossRef]
    [Google Scholar]
  38. Swaminathan, B., Matar, G. M., Reeves, M. W., Graves, L. M., Ajello, G., Bibb, W. F., Helsel, L. O., Morales, M., Dronavalli, H. & other authors ( 1996; ). Molecular subtyping of Neisseria meningitidis serogroup B: comparison of five methods. J Clin Microbiol 34, 1468–1473.
    [Google Scholar]
  39. Swartley, J. S., Marfin, A. A., Edupuganti, S., Liu, L. J., Cieslak, P., Perkins, B., Wenger, J. D. & Stephens, D. S. ( 1997; ). Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 94, 271–276.[CrossRef]
    [Google Scholar]
  40. Taha, M. K., Alonso, J. M., Cafferkey, M., Caugant, D. A., Clarke, S. C., Diggle, M. A., Fox, A., Frosch, M., Gray, S. J. & other authors ( 2005; ). Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol 43, 144–149.[CrossRef]
    [Google Scholar]
  41. Thompson, E. A. L., Feavers, I. M. & Maiden, M. C. J. ( 2003; ). Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149, 1849–1858.[CrossRef]
    [Google Scholar]
  42. Trotter, C. L., Chandra, M., Cano, R., Larrauri, A., Ramsay, M. E., Brehony, C., Jolley, K. A., Maiden, M. C., Heuberger, S. & other authors ( 2007; ). A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31, 27–36.[CrossRef]
    [Google Scholar]
  43. Urwin, R., Russell, J. E., Thompson, E. A., Holmes, E. C., Feavers, I. M. & Maiden, M. C. ( 2004; ). Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72, 5955–5962.[CrossRef]
    [Google Scholar]
  44. van den Dobbelsteen, G. P. J. M., van Dijken, H. H., Pillai, S. & van Alphen, L. ( 2007; ). Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25, 2491–2496.[CrossRef]
    [Google Scholar]
  45. Vogel, U., Claus, H. & Frosch, M. ( 2000; ). Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 342, 219–220.[CrossRef]
    [Google Scholar]
  46. Yazdankhah, S. P., Kriz, P., Tzanakaki, G., Kremastinou, J., Kalmusova, J., Musilek, M., Alvestad, T., Jolley, K. A., Wilson, D. J. & other authors ( 2004; ). Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 42, 5146–5153.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.2007/014761-0
Loading
/content/journal/micro/10.1099/mic.0.2007/014761-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error